Citigroup
CHRS icon

Citigroup’s Coherus Oncology CHRS Stock Holding History

Citigroup’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$8K – 7679
2018
Q3 		$8K Sell
500
-500
-50% -$8.86K ﹤0.01% 7401
2018
Q2 		$14K Sell
1,000
-300
-23% -$4.29K ﹤0.01% 7067
2018
Q1 		$14K Sell
1,300
-1,100
-46% -$12K ﹤0.01% 6907
2017
Q4 		$21K Buy
2,400
+200
+9% +$2.14K ﹤0.01% 6702
2017
Q3 		$29K Sell
2,200
-2,900
-57% -$38.4K ﹤0.01% 6269
2017
Q2 		$73K Buy
5,100
+4,200
+467% +$80.8K ﹤0.01% 5553
2017
Q1 		$19K Buy
900
+300
+50% +$7.38K ﹤0.01% 6274
2016
Q4 		$17K Buy
+600
New +$16.8K ﹤0.01% 6584

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return